Press Releases

SAN FRANCISCO --(BUSINESS WIRE)--Jun. 16, 2022-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Kevin Appelbaum ,

SAN FRANCISCO --(BUSINESS WIRE)--Jun. 9, 2022-- Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that it will participate in

SAN FRANCISCO --(BUSINESS WIRE)--Jun. 8, 2022-- Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that the U.S.

SAN FRANCISCO --(BUSINESS WIRE)--Jun. 7, 2022-- Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join

Leading Medical Experts to Discuss Promising Developments on Prescription Digital Therapeutics and Nutritional Cognitive Behavioral Therapy for Type 2 Diabetes Patients SAN FRANCISCO --(BUSINESS WIRE)--May 19, 2022-- Better Therapeutics, Inc . (“Better Therapeutics”, NASDAQ: BTTX), a prescription

Reported positive primary endpoint results from pivotal trial of BT-001 after 90 days of treatment for type 2 diabetes Represents a first-in-class randomized, controlled clinical trial of a prescription digital therapeutic (PDT) for treating a cardiometabolic disorder Data supports filing of a de

SAN FRANCISCO --(BUSINESS WIRE)--May 5, 2022-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will release its first

First Study of Nutritional Cognitive Behavioral Therapy for Fatty Liver Disease and Expanded Real-World Evidence Studies for Type 2 Diabetes Follow Promising Primary Endpoint Clinical Trial Data SAN FRANCISCO --(BUSINESS WIRE)--Apr. 6, 2022-- Better Therapeutics, Inc.

SAN FRANCISCO --(BUSINESS WIRE)--Apr. 4, 2022-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Kevin Appelbaum ,

Company Highlights Positive Pivotal Clinical Trial Data for BT-001, a Prescription Digital Therapeutic for Type 2 Diabetes SAN FRANCISCO --(BUSINESS WIRE)--Mar. 28, 2022-- Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive